ARA-290 (Cibinetide), Research Reference

ARA-290 (also known as Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface peptide region of erythropoietin (EPO). It was engineered to selectively activate the innate repair receptor (IRR), a heterodimeric receptor complex that mediates EPO’s tissue-protective and anti-inflammatory properties, while producing no erythropoietic (red-blood-cell-stimulating) effects. Phase 2 clinical trials have investigated ARA-290 in sarcoidosis-associated small fiber neuropathy and type 2 diabetes-associated neuropathy, where it demonstrated improvements in neuropathic symptoms and directly measurable nerve fiber regeneration.

Quick Reference

Overview

ARA-290 was developed by researchers Michael Brines and Anthony Cerami, who identified that erythropoietin signals through two pharmacologically distinct receptor systems. The classical EPO receptor homodimer drives erythropoiesis (red blood cell production), and its activation accounts for the elevated hematocrit, cardiovascular risk, and thrombosis concerns associated with therapeutic EPO use in non-anemic patients. The second system, subsequently termed the innate repair receptor (IRR), is a heterodimer formed by the erythropoietin receptor and the beta-common receptor (CD131), and mediates EPO’s tissue-protective, neuroprotective, and anti-inflammatory effects independently of erythropoiesis.

ARA-290 was designed to engage selectively with the IRR, derived from the helix-B surface peptide sequence of EPO, a region of the molecule with high affinity for the IRR heterodimer but minimal affinity for the classical EPO receptor homodimer. This design means that Cibinetide retains EPO’s tissue-repair signaling while eliminating the erythropoietic activity that limits EPO’s use in non-anemic neuropathy populations.

Research on ARA-290 has focused primarily on neuropathy, where small fiber degeneration is a measurable end point. Small fiber neuropathy affects unmyelinated C-fibers and thinly myelinated A-delta fibers that mediate pain, temperature, and autonomic function, and currently lacks any approved disease-modifying treatment. ARA-290 is the first compound in its mechanistic class to advance to Phase 2 clinical trials for this indication.

Mechanism of Action

Innate Repair Receptor Activation

The innate repair receptor (IRR) is formed by the non-covalent association of the erythropoietin receptor (EPOR) and the beta-common receptor subunit (CD131), also known as the beta-c receptor or the GM-CSF receptor common subunit. This heterodimer is expressed on cells in injured and inflamed tissues, including neurons, glial cells, endothelial cells, and immune cells.

When ARA-290 or Cibinetide binds the IRR, it initiates intracellular signaling distinct from the JAK2/STAT5 pathway activated by the classical EPOR homodimer. IRR activation engages pathways associated with cellular survival, anti-apoptotic signaling, and suppression of pro-inflammatory cytokine cascades. The net effect in injured tissue is a shift in the local signaling environment away from inflammation-dominated states and toward repair-oriented states, supporting nerve fiber survival and regeneration in neuropathy models.

Mechanistic Contrast with NMDA Receptor-Targeting Compounds

Unlike compounds such as ketamine, which produce neuropathic pain relief partly through NMDA receptor antagonism, ARA-290 has no affinity for the NMDA receptor. The mechanisms are pharmacologically distinct: NMDA receptor blockade interrupts excitatory glutamatergic signaling that contributes to central sensitisation and neuropathic pain, while ARA-290 operates via IRR activation on peripheral and central tissue cells. This distinction is relevant in research contexts where investigators seek compounds targeting the peripheral pathology of small fiber degeneration rather than centrally modulating pain perception.

Reported Protocols

The following information reflects dosing and administration approaches from published Phase 2 clinical trial protocols. ARA-290 dosing is less standardised in research contexts than that of more widely discussed compounds, and the information below should be understood as deriving from formal trial settings rather than community research convention.

Clinical Trial Administration

Subcutaneous injection is the primary administration route reported in the sarcoidosis and diabetic neuropathy Phase 2 trials. Intravenous administration was used in some earlier trial contexts. The Phase 2b sarcoidosis-associated small fiber neuropathy trial used a 28-day daily subcutaneous dosing regimen, during which corneal nerve fiber regrowth was assessed by confocal microscopy as a primary endpoint.

Daily Dosing Rationale

Daily dosing is the approach used in published ARA-290 / Cibinetide trial protocols. Some sources suggest that the IRR may require sustained or repeated activation to produce the nerve regeneration effects observed in clinical trials, rather than a single acute receptor engagement. This rationale is presented as a proposed mechanism in research literature and has not been formally validated in dose-interval studies. Research-context daily dosing is distinct from the once-weekly or twice-weekly schedules common in many other research peptide protocols.

Reconstitution

ARA-290 is commonly supplied as a 10 mg lyophilized vial. A commonly reported reconstitution approach adds 1.0 mL of bacteriostatic water or sterile water, yielding a 10 mg/mL solution. This reconstitution approach is commonly reported in research contexts and is not a universal or regulatory-approved standard. Add diluent slowly along the inside wall of the vial and swirl gently; do not shake. See the Reconstitution Guide for step-by-step instructions.

Reported Effects

The following effects are based on published clinical trial data and preclinical studies. Preclinical findings from animal models are distinguished from human trial findings throughout.

Human Trial Findings: Sarcoidosis-Associated Small Fiber Neuropathy

A Phase 2b randomised controlled trial in patients with sarcoidosis-associated small fiber neuropathy reported the following:

• Neuropathic and autonomic symptoms: Statistically significant improvements in symptom scores assessed using the small fiber neuropathy screening list (SFNSL) questionnaire in patients receiving ARA-290 compared to placebo.
• Quality of life: Significant improvements in quality of life measures in the ARA-290 group.
• Corneal nerve fiber regrowth: After 28 days of daily treatment, patients receiving ARA-290 showed directly measurable regrowth of small nerve fibers in the cornea, as assessed by corneal confocal microscopy. This finding was specific to the cornea; regrowth in the epidermis was not reported in this trial.

This finding of measurable structural nerve fiber regeneration in a 28-day treatment window is the most clinically notable finding from the published ARA-290 literature.

Human Trial Findings: Type 2 Diabetes-Associated Neuropathy

Phase 2 trials in patients with type 2 diabetes-associated neuropathy reported similar improvements in neuropathic symptoms alongside improvements in metabolic parameters including measures of insulin sensitivity and metabolic control. The combination of neuropathic and metabolic improvements in a single compound is an area of ongoing research interest given the dual pathology of diabetic neuropathy.

Evidence Limitations

The ARA-290 evidence base carries important limitations that researchers should weigh:

• Published human evidence is limited to Phase 2 trials. No Phase 3 trials of ARA-290 or Cibinetide have been completed as of this writing.
• The published trials were conducted in single or limited-centre settings. Independent multicenter replication has not yet occurred.
• The corneal nerve fiber finding was not replicated in the epidermis, which is important for interpreting the scope of the regeneration observed.
• The metabolic improvements in the diabetic neuropathy population require independent confirmation.

This evidence profile is honest about its early-stage nature. The mechanistic rationale is well-grounded and the Phase 2b signals are positive, but ARA-290 has not yet crossed the validation threshold that completed Phase 3 and independent replication provide.

Preclinical Findings (Animal Models)

Preclinical studies in animal models have investigated ARA-290 in the following contexts. These findings are distinct from the human clinical evidence above and should not be taken as confirming human efficacy in these areas:

• Colitis models: IRR activation via ARA-290 demonstrated anti-inflammatory effects in preclinical colitis models, reducing inflammatory cytokine expression and tissue damage markers.
• Cerebral ischemia models: Preclinical studies reported neuroprotective effects following IRR activation in models of cerebral ischemia, with reductions in infarct size and improved neurological outcomes in rodent models.
• Autoimmune neuritis models: IRR activation was associated with reduced peripheral nerve inflammation and improved motor function in animal models of experimental autoimmune neuritis.

These preclinical findings provide supporting evidence for the mechanistic rationale but do not constitute human evidence of efficacy in these additional indications.

Reported Side Effects

In the Phase 2 clinical trial populations investigating ARA-290 in sarcoidosis-associated small fiber neuropathy and diabetic neuropathy, no significant drug-related adverse effects were reported in published trial data. The compound appeared well tolerated in these populations over the 28-day treatment periods studied.

Precautionary Note: Cancer and Myeloproliferative Disorders

Because ARA-290 and Cibinetide are structurally derived from erythropoietin, secondary research sources and some clinical commentary recommend caution regarding use in individuals with active cancer or myeloproliferative disorders. This precautionary recommendation reflects ARA-290’s structural relationship to EPO, for which risks in cancer populations are established, even though ARA-290 is specifically engineered to be non-erythropoietic. This is a precautionary note based on the compound’s EPO-derived origin, not a confirmed risk demonstrated in ARA-290 trial data specifically.

Injection Site

Subcutaneous injection site reactions are a general consideration for daily injected peptide protocols and have not been distinguished as a notable safety concern in published ARA-290 trial summaries.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Freezer (-20°C): Required for lyophilized storage
• Light sensitivity: Protect from light; store in opaque or amber packaging
• Do not store at room temperature for extended periods

Reconstituted Solution

• Refrigerator (2-8°C): Required for reconstituted solution
• Use within 14 days of reconstitution
• Protect from light
• Do not freeze reconstituted solution
• Discard if the solution appears cloudy, discoloured, or contains particulate matter

Reconstitution

A commonly reported approach: add 1.0 mL of bacteriostatic water or sterile water to a 10 mg lyophilized vial along the inside wall of the vial. Swirl gently; do not shake. This yields a 10 mg/mL solution. This reconstitution approach is commonly reported and is not a regulatory- approved standard. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

What is ARA-290 (Cibinetide)? ARA-290, also known as Cibinetide, is a synthetic 11-amino-acid peptide derived from the helix-B surface region of erythropoietin, developed by Araim Pharmaceuticals. It selectively activates the innate repair receptor (IRR), the tissue-protective signaling pathway of EPO, without triggering erythropoiesis. Research interest has focused on its potential role in small fiber neuropathy, including sarcoidosis-associated and diabetic neuropathy, where Phase 2 trials have shown improvements in symptoms and measurable nerve fiber regeneration in the cornea.

How does ARA-290 differ from erythropoietin (EPO)? EPO signals through two separate receptor systems: the classical EPO receptor homodimer, which stimulates red blood cell production, and the innate repair receptor (IRR), which mediates tissue-protective and anti-inflammatory effects. ARA-290 is derived from the helix-B surface peptide of EPO and is selective for the IRR, producing no stimulation of the erythropoietic receptor homodimer. This eliminates the elevated hematocrit, cardiovascular, and thrombosis concerns that limit EPO’s therapeutic use in non-anemic patients, allowing IRR activation to be studied in neuropathy populations safely.

What clinical trial evidence exists for ARA-290? ARA-290 has been studied in Phase 2 trials. A Phase 2b trial in sarcoidosis-associated small fiber neuropathy showed significant improvements in neuropathic and autonomic symptoms and quality of life, with 28-day treatment associated with measurable regrowth of small nerve fibers in the cornea (assessed by confocal microscopy). This corneal nerve fiber finding is the most specific structural outcome reported. Phase 2 data also exists for diabetic neuropathy, with neuropathic improvements and metabolic benefits reported. No Phase 3 trials have been completed; independent multicenter replication has not yet occurred.

Does ARA-290 increase red blood cell count? No. ARA-290 is specifically engineered to have no erythropoietic activity. Its selectivity for the IRR over the classical EPO receptor homodimer is a primary design feature. Published Phase 2 trial data in sarcoidosis and diabetic neuropathy populations did not show erythropoietic effects. This distinguishes Cibinetide from EPO and is a prerequisite for its use in non-anemic neuropathy research populations.

What is the innate repair receptor? The innate repair receptor (IRR) is a receptor heterodimer formed by the erythropoietin receptor (EPOR) and the beta-common receptor (CD131), also known as the beta-c or GM-CSF receptor common subunit. Characterised by researchers Michael Brines and Anthony Cerami, the IRR is expressed on injured tissue cells including neurons, glial cells, and endothelial cells, and is activated by EPO in states of tissue stress. IRR activation shifts the signaling environment in injured tissue toward repair and away from inflammation, supporting cell survival and tissue regeneration. ARA-290 was designed specifically to activate the IRR without triggering the classical erythropoietic pathway.

Related Pages

Goals: Neuroprotection · Inflammation · Recovery & Healing

Also see: BPC-157 · Semax · KPV

References & Further Reading

• Dahan A, et al. (2017). Benefit of ARA 290 in patients with sarcoidosis-associated small fiber neuropathy. A Phase 2b randomised, double blind, placebo controlled study. Pain Reports, 2(2), e586. PMC5741312 PMC →
• Brines M, et al. (2017). ARA 290, a nonerythropoietic peptide engineered from the innate repair receptor ligand of erythropoietin, corrects metabolic dysfunction and improves neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine, 20(1), 658-669.
• Dahan A, et al. (2017). Corneal nerve fiber regrowth in patients with sarcoidosis-associated small fiber neuropathy following treatment with the erythropoietin analogue ARA 290. Investigative Ophthalmology and Visual Science, 58(2), 1136-1145. doi:10.1167/iovs.16-21291 →
• Brines M, Cerami A. (2012). The receptor that tames the innate immune response. Molecular Medicine, 18(1), 486-496.